Filing Flows › C4 Therapeutics (CCCC) › Q2 2026 › vs Q2 2025
C4 Therapeutics (CCCC) Q2 2026 vs Q2 2025 (year over year)
C4 Therapeutics's revenue rose $178K (+3%) from $6.5M in Q2 2025 to $6.6M in Q2 2026.
C4 Therapeutics, Q2 2026: revenue $6.6M (+3% year over year), operating margin -397.9%, net loss $23.6M, operating cash flow −$1.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $6.6M | $6.5M | $178K | +3% |
| Other income, net | $2.8M | $2.5M | $307K | +12% |
| Net loss | $23.6M | $26.0M | −$2.4M | -9% |
| Costs & expenses | $33.1M | $35.0M | −$1.9M | -5% |
| Operating costs | $33.1M | $35.0M | −$1.9M | -5% |
| Research & development | $24.5M | $26.2M | −$1.7M | -7% |
| General & admin | $8.6M | $8.8M | −$174K | -2% |
| Operating cash sources | $23.6M | $26.0M | −$2.4M | -9% |
| Depreciation & amortization | $292K | $615K | −$323K | -53% |
| Share-based compensation | $3.0M | $5.0M | −$2.0M | -39% |
| Working capital & other | $18.7M | $8.4M | $10.4M | +124% |
| Cash used in operations | $1.6M | $12.1M | −$10.5M | -87% |
| Net loss absorbed | $23.6M | $26.0M | −$2.4M | -9% |
Questions
How much did C4 Therapeutics's revenue grow year over year in Q2 2026?
C4 Therapeutics's revenue rose $178K (+3%) from $6.5M in Q2 2025 to $6.6M in Q2 2026.